MNPR vs XYL · $431.4M cap vs P/E 27, rev $4.46B
Monopar Therapeutics Inc (MNPR) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Monopar Therapeutics Inc (MNPR) is a biotechnology company listed on US.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported MNPR revenue for 2026-06-30 was $0. Net income was -$9.2M. MNPR currently screens at market cap $431.4M.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
MNPR currently screens at market cap $431.4M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the MNPR and XYL stock pages for the full models.
Not investment advice.